CareFusion 213, LLC Initiates Class I Recall of ChloraPrep Applicators Due to Aspergillus Penicilloides Contamination
CareFusion 213, LLC, a Becton, Dickinson and Company subsidiary, executed a Class I recall of 2.8 million ChloraPrep applicators due to *Aspergillus Penicilloides* contamination. This global event, impacting 16 countries, underscores critical non-sterility risks in pre-operative skin preparations. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate similar supply chain disruptions.
FDA Class I Recall: Non-Sterility of ChloraPrep Applicators
CareFusion 213, LLC, a key subsidiary of Becton, Dickinson and Company, initiated a Class I recall, D-1510-2020, for its ChloraPrep With Tint 3 mL applicators. This critical regulatory action, commenced on June 23, 2020, stemmed from confirmed non-sterility, specifically the presence of *Aspergillus Penicilloides*. The affected product, identified by NDC 054365-400-11, contains a formulation of 2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl alcohol (IPA), crucial components for pre-operative skin antisepsis. The FDA's Class I classification signifies that use of or exposure to the contaminated product carries a reasonable probability of causing serious adverse health consequences or death. For procurement directors and regulatory affairs heads, this event highlights the severe implications of microbial contamination in sterile medical products, demanding immediate review of supplier quality assurance programs. The recall ultimately concluded on September 28, 2022, indicating the resolution of the immediate market risk, but the underlying lessons for quality control remain paramount. The presence of *Aspergillus Penicilloides* in a product intended for use on patients, particularly in surgical settings, presents a direct and unacceptable risk of infection, potentially leading to severe morbidity or mortality.
Global Supply Chain Disruption: Impact of Contaminated Medical Devices
The recall encompassed a substantial volume of 2,800,800 applicators, originating from CareFusion's facility in El Paso, TX 79912, United States. The distribution footprint was extensive, reaching 16 distinct international markets and territories, including Puerto Rico, Guam, the United Arab Emirates, Bahrain, Brazil, the Democratic Republic of the Congo, Chile, Colombia, the United Kingdom, Hong Kong, Israel, Kuwait, Oman, Qatar, Saudi Arabia, and Singapore. This broad geographic reach meant significant supply chain disruption for healthcare providers and distributors across multiple continents. For supply chain VPs and business development executives, this incident underscores the inherent vulnerabilities in global distribution networks when critical quality control failures occur at the manufacturing source. The sudden withdrawal of nearly three million units of a widely used pre-operative antiseptic necessitated rapid sourcing of alternative products, potentially leading to increased costs, delays in medical procedures, and compromised patient care in affected regions. The commercial implications extend beyond immediate financial losses to include reputational damage for both the manufacturer and its distribution partners, emphasizing the need for robust contingency planning and multi-source procurement strategies.
Regulatory Compliance Imperatives for Sterile Product Manufacturing
The recall of ChloraPrep applicators was initiated voluntarily by CareFusion 213, LLC, indicating the firm's proactive identification of the non-sterility issue or a swift response to initial findings. Despite being firm-initiated, the FDA's Class I designation underscores the severity of the underlying quality defect. This event serves as a critical reminder for regulatory affairs heads and procurement directors regarding the stringent compliance requirements for sterile drug products and medical devices. Manufacturers must maintain comprehensive quality management systems, including robust environmental monitoring programs, stringent aseptic processing controls, and rigorous finished product sterility testing, to prevent microbial contamination like *Aspergillus Penicilloides*. The recall affected numerous product lots, with expiry dates ranging from June 25, 2020, to January 31, 2023, highlighting a potentially systemic issue over an extended production period. The termination of the recall on September 28, 2022, suggests that CareFusion successfully implemented corrective actions and removed affected product from the market, but the incident will undoubtedly lead to heightened scrutiny from regulatory bodies and customers alike regarding their sterility assurance processes.
Mitigating Future Supply Chain Risks and Quality Control
For procurement directors and supply chain VPs, the CareFusion 213, LLC ChloraPrep recall necessitates a comprehensive re-evaluation of supplier qualification and ongoing monitoring protocols for all sterile products. Relying on a single source or failing to conduct thorough audits of manufacturing facilities, particularly those with extensive global distribution, can expose organizations to significant operational and reputational risks. This incident, while specific to ChloraPrep, mirrors broader industry challenges in maintaining consistent quality control, as evidenced by recent parallel events such as SCA Pharmaceuticals' Class II recall of subpotent Heparin Sodium or Motto International Corp's Class I recall of unapproved drugs with undeclared active ingredients. These instances collectively underscore the pervasive nature of quality control vulnerabilities across the chemical and life sciences sectors. Business development executives must integrate supply chain resilience and robust quality assurance into their strategic planning, recognizing that product integrity is a non-negotiable factor for market access and sustained growth. Proactive engagement with suppliers to understand their sterility assurance programs, coupled with geographic diversification of sourcing, is crucial to safeguard against future disruptions and ensure patient safety.